omega conotoxin MVIIA - CAS 107452-89-1
Not Intended for Therapeutic Use. For research use only.
Category:
ADCs
Product Name:
omega conotoxin MVIIA
Catalog Number:
107452-89-1
CAS Number:
107452-89-1
Description:
ω conotoxin MVIIA (omega conotoxin MVIIA) has been isolated from the venom of the cone Conus magus. Omega-conotoxins act at presynaptic membranes, they bind and block voltage-sensitive calcium channels (VSCC).
Molecular Weight:
2639.2
Molecular Formula:
C102H172N36O32S7
COA:
Inquire
MSDS:
Inquire
Tag:
ADCs Cytotoxin
Chemical Structure
CAS 107452-89-1 omega conotoxin MVIIA

Related ADCs Cytotoxin Products


Imperialine iodomethylate

A highly active peripheral M2-cholinoblocker alkaloid. Imperialine is extracted from Petilium eduardi and Petilium raddeanae (Liliaceae family)

CAS 5489-15-6 O-Methylisocorydine Iodomethylate

O-Methylisocorydine Iodomethylate
(CAS: 5489-15-6)

Aporphin alkaloid derivative of Isocorydine from plants of the Corydalis genus, Fumariaceae, a long-lasting ganglioblocker, with a sympathetic/parasympathetic a...

CAS 11094-61-4 Erabutoxin A

Erabutoxin A
(CAS: 11094-61-4)

An antagonist of the nicotinic acetylcholine receptor at the neuromuscular junction. Erabutoxin B from Laticauda semifasciata (Sea Snake)

CAS 474645-27-7 MMAE

MMAE
(CAS: 474645-27-7)

Monomethyl Auristatin E (MMAE) is a synthetic analog of dolastatin 10 that similarly inhibits tubulin polymerization and exhibits potent cytotoxicity. It is com...

Bj-xtrlT (recombinant)

An excitatory scorpion toxin. Polypeptide, of 77 amino acids cross-linked by 4 disulfide bridges. Recombinant toxin produced in<br/>Escherichia coli initialy fr...

CAS 86992-41-8 Lapidine

Lapidine
(CAS: 86992-41-8)

Carothane complex ester , from plants of the Umbelliferae family.

Tazettine
(CAS: 507-79-9)

Indole alkaloid Amaryllidaceae Fam. Plants

CAS 220355-66-8 Saxitoxin diacetate

Saxitoxin diacetate
(CAS: 220355-66-8)

Saxitoxin (STX) is a potent neurotoxin and the best-known paralytic shellfish toxin (PST). Ingestion of saxitoxin, usually by consumption of shellfish contamina...

CAS 134710-25-1 Calciseptine

Calciseptine
(CAS: 134710-25-1)

Calciseptine is a natural neurotoxin isolated from the black mamba Dendroaspis p. polylepis venom. This toxin consists of 60 amino acids with four disulfide bon...

Notexine Np
(CAS: 37223-96-4)

Notexin exerts both presynaptic (blocks the release of acetylcholine) and myotoxic<br/>activities

Brevetoxin PbTx-9

An activator of voltage-sensitive Na+ channels, a suite of cyclic polyether compounds produced naturally by a species of dinoflagellate known as Karenia brevis....

LK-66 M

A muscarinic receptors antagonist.

CAS 3563-63-1 Diquine

Diquine
(CAS: 3563-63-1)

a nicotinic cholinoreceptor antagonist at the neuromuscular junction; curare-like ganglioblocker. Bis-quaternary quinuclidine derivative, , synthetic.

CAS 58-73-1 Diphenhydramine

Diphenhydramine
(CAS: 58-73-1)

A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and ...

CAS 153-18-4 Rutin

Rutin
(CAS: 153-18-4)

Rutin is colored brown by tobacco enzyme under experimental conditions

Pentazoline hydrochloride
(CAS: 61939-12-6)

Synthetic, an inhibitor of monoamine oxydase.

Benzoylheteratisine hydrochloride
(CAS: 1262758-10-0)

A Na+ channel blocker; potent antiarrhythmic, inhibits voltage-gated Na+ channels in rat brain synaptosomes.

Seco-DuocarmycinDME

Seco-Duocarmycin DME is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

CAS 60-38-8 3-Acetyl-Strophanthidin

3-Acetyl-Strophanthidin
(CAS: 60-38-8)

An ATPase inhibitor.

Seco-DuocarmycinDMG
(CAS: 1613286-55-7)

Seco-Duocarmycin DMG is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

Reference Reading


1.Clinical Uses of Intrathecal Therapy and Its Placement in the Pain Care Algorithm.
Pope JE1, Deer TR2, Bruel BM3, Falowski S4. Pain Pract. 2016 Feb 23. doi: 10.1111/papr.12438. [Epub ahead of print]
Intrathecal drug delivery is an effective treatment option for patients with severe chronic pain who have not obtained adequate analgesia from more conservative therapies (eg, physical therapy, systemic opioids, nonsteroidal anti-inflammatory drugs, antidepressants, and anticonvulsants). This review focuses on, but is not limited to, the 2 agents currently approved by the U.S. Food and Drug Administration for intrathecal analgesia: preservative-free morphine and ziconotide (a nonopioid, selective N-type calcium channel blocker). We describe the appropriate use of intrathecal therapy in the management of severe chronic pain, based on current best practices. Topics addressed here include patient selection, trialing, dosing and titration, adverse event profiles, long-term management, intrathecal therapy for cancer-related pain, and the placement of intrathecal therapy in the pain care algorithm. In appropriately selected patients with chronic pain, intrathecal therapy can provide substantial pain relief with improved functioning and quality of life.
2.Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
McDowell GC 2nd1, Pope JE2. Neuromodulation. 2016 Feb 9. doi: 10.1111/ner.12392. [Epub ahead of print]
INTRODUCTION: Ziconotide is a non-opioid analgesic for intrathecal (IT) administration. The aim of this review is to provide a comprehensive and clinically relevant summary of the literature on dosing and administration with IT ziconotide in the management of refractory chronic pain, and to describe novel dosing strategies intended to improve clinical outcomes.
3.ZiconotideMonotherapy: A Systematic Review of Randomised Controlled Trials.
Brookes ME1, Eldabe S, Batterham A. Curr Neuropharmacol. 2016 Feb 10. [Epub ahead of print]
INTRODUCTION: Chronic neuropathic pain is difficult to treat and is often refractory to most modalities of treatment. Ziconotide is a novel, potent, non-opioid, calcium channel blocking agent which has been shown in clinical trials to be effective in treating chronic neuropathic pain.
4.Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain.
Manda P1, Kushwaha AS1, Kundu S2, Shivakumar HN3, Jo SB1, Murthy SN4. J Control Release. 2016 Feb 28;224:69-76. doi: 10.1016/j.jconrel.2015.12.044. Epub 2015 Dec 28.
The purpose of the current study was to investigate the plausibility of delivery of ziconotide to the cerebrospinal fluid (CSF) via intranasal administration. Ziconotide was administered either in the form of solution or Kolliphor P 407 gels (KP 407) intranasally in Sprague-Dawley rats. The effect of incorporation of chitosan in the formulation was also investigated. Time course of drug in the CSF was investigated by collecting CSF from cisterna magna. Pharmacokinetics of ziconotide in CSF following intrathecal and intravenous (i.v.) administration of ziconotide was investigated. Upon intrathecal administration the elimination rate constant of ziconotide in CSF was found to be 1.01±0.34h(-1). The Cmax and Tmax of ziconotide in CSF following intravenous administration were found to be 37.78±6.8ng/mL and ~2h respectively. The time required to attain maximum concentration (Tmax) in CSF was less upon intranasal administration (15min) compared to i.